A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
Latest Information Update: 27 Feb 2024
At a glance
- Drugs Pelecopan (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms REDEEM-2
- Sponsors BioCryst Pharmaceuticals
- 03 Feb 2024 This Trial has been Discontinued in Italy, According to European Clinical Trials Database record
- 07 Jan 2024 This Trial has been completed in Czech republic as per European Clinical Trials Database record(global end date-18 Sep 2023).
- 15 Dec 2022 According to a BioCryst Pharmaceuticals media release, based on new competitive data recently presented at the American Society of Hematology (ASH) annual meeting, the company no longer believes that BCX9930 would be commercially competitive, and is discontinuing the development of BCX9930. This decision allows the company to fully focus its complement inhibitor development efforts on BCX10013